Open AccessSpecific and cross-reactive immune response against Mycobacterium tuberculosis antigens in mice immunized with proteoliposomes from Mycobacterium bovis BCG
Author(s) -
Nadine Álvarez,
Daymí Serpa,
Ramlah Kadir,
Yanely Tirado,
Reinier Borrero,
Sonsire Fernández,
Rubén Cabrera,
Yolanda Valdés,
Caridad Zayas,
Reinaldo Acevedo,
Luís Izquierdo,
María E. Sarmiento,
Norazmi Mohd Nor,
José Luís Pérez,
Armando Acosta
Publication year - 2017
Publication title -
asian pacific journal of tropical biomedicine/asian pacific journal of tropical biomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.507
H-Index - 61
eISSN - 2588-9222
pISSN - 2221-1691
DOI - 10.1016/j.apjtb.2016.12.013
Subject(s) - immunogenicity , adjuvant , antigen , immune system , mycobacterium bovis , mycobacterium tuberculosis , tuberculosis vaccines , humoral immunity , microbiology and biotechnology , antibody , immunology , immunoglobulin g , biology , tuberculosis , virology , medicine , pathology
Objective: To characterize the immunogenicity and the induction of cross-reactive responses against Mycobacterium tuberculosis (M. tuberculosis) of a proteoliposome (PL) from Mycobacterium bovis Bacillus Calmette–Guérin (BCG) with and without alum hydroxide (AL) as adjuvant (PLBCG-AL and PLBCG, respectively) in BALB/c mice.Methods: BALB/c mice were inoculated with phosphate buffer solution, BCG, PLBCG and PLBCG-AL. The humoral immunogenicity was determined by ELISA [immunoglobulin G (IgG), IgG1 and IgG2a] and the cellular immunogenicity was evaluated in vivo by delayed type hypersensitivity. The humoral cross-reactive response against M. tuberculosis was determined by Western blot.Results: Sera from animals immunized with PLBCG-AL and PLBCG showed significant increase in specific total IgG and IgG1 antibodies and the presence of cross-reactive antibodies against M. tuberculosis antigens, which were more intense with the use of alum as adjuvant. Mice immunized with PLBCG and PLBCG-AL also showed a specific cellular response in vivo.Conclusions: The cellular and humoral immunogenicity of PLBCG and the capacity to induce cross-reactive responses against M. tuberculosis is in agreement with the protective capacity previously demonstrated by this vaccine candidate and supports the continuation of its evaluation in further stages